These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21482494)

  • 21. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
    Caruba T; Cottu PH; Madelaine-Chambrin I; Espié M; Misset JL; Gross-Goupil M
    Breast J; 2007; 13(2):165-71. PubMed ID: 17319858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
    Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
    Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
    Zielinski CC
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Wang J; Fan Y; Xu B
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
    Modi S; Currie VE; Seidman AD; Bach AM; Panageas KS; Theodoulou M; Moasser MM; D'Andrea GM; Lake DE; Choi J; Norton L; Hudis CA
    Clin Breast Cancer; 2005 Apr; 6(1):55-60. PubMed ID: 15899073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
    Laessig D; Stemmler HJ; Vehling-Kaiser U; Fasching PA; Melchert F; Kolbl H; Stauch M; Maubach P; Scharl A; Morack G; Meerpohl H; Weber B; Kalischefski B; Heinemann V
    Oncology; 2007; 73(5-6):407-14. PubMed ID: 18515981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy.
    Chitapanarux I; Lorvidhaya V; Kamnerdsupaphon P; Tharavichitkul E; Trakultivakorn H; Somwangprasert A; Sumitsawan S; Srisukho S; Watcharachan K; Sukthomya V
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):761-6. PubMed ID: 16770093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
    Fontaine C; Renard V; Van den Bulk H; Vuylsteke P; Glorieux P; Dopchie C; Decoster L; Vanacker L; de Azambuja E; De Greve J; Awada A; Wildiers H
    Breast Cancer Res Treat; 2019 Aug; 176(3):607-615. PubMed ID: 31069589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
    Borson R; Harker G; Reeves J; Beck T; Hager S; Horvath W; Jones M; Tillinghast G; Arrowsmith E; Harrer G; Kudrik FJ; Malamud SC; Bromund J; Zeigler H; Tai DF; Kornberg LJ; Obasaju C; Orlando M; Yardley DA
    Clin Breast Cancer; 2012 Oct; 12(5):322-30. PubMed ID: 23040000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
    Erten C; Demir L; Somali I; Alacacioglu A; Kucukzeybek Y; Akyol M; Can A; Dirican A; Bayoglu V; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(6):3711-7. PubMed ID: 23886170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.